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Abstract A simple, sensitive and selective extractive spectrophotometric method for the determination of 
quetiapine fumarate (QTF) in bulk drug, tablets and spiked human urine sample is described. The method 
is based on the formation of a chloroform extractable yellow ion-pair complex between basic nitrogen of 
the drug (QTF) and the dye quinoline yellow (QY) in acetate-hydrochloride buffer (pH 2.56) medium. 
The formed ion-pair complex exhibited an absorption maximum at 420 nm. Beer’s law is obeyed over the 
concentration range 2.5–25 µg mL–1 with an apparent molar absorptivity value of  
2.02 × 104 L mol–1 cm–1. The Sandell sensitivity, limits of detection (LOD) and quantification values are 
also reported. The composition of the ion-pair was established by Job’s continuous variations method and 
it was found to be 1:1 (QTF:QY). The proposed method was successfully applied for the determination of 
QTF in bulk drug, tablets and spiked human urine without any interference. (doi: 10.5562/cca1770)  
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INTRODUCTION 
Quetiapine fumarate (QTF) is an atypical antipsychotic 
drug.1 It is a dibenzothiazepine derivative chemically 
known as {2-(2-(4-dibenzo[b,f] [1,4]thiazepine-11-yl-1-
piperazinyl)ethoxy)ethanol, fumaric acid (1:2 salt; for-
mula C29H33N3O10S; molecular weight: 615.66)} (Fig-
ure 1). QTF is prescribed for treatment of schizophrenia 
and other psychotic or schizoactive disorders.2–4 QTF 
was approved by the FDA for the treatment of Bipolar I 
(Bipolar II) disorder as a monotherapeutic agent.5 
QTF is not official in any pharmacopoeia. Several 
analytical methods such as HPLC,6–13 chemilu-
minescence spectrometry,14 electrospray ionization 
MS,15–18 tandem MS/MS detection,19–22 UPLC with 
tandem MS detection,23,24 GC25,26 and voltammetry27 are 
found in the literature for the determination of QTF in 
biological materials. 
Various techniques such as polarography,28 capil-
lary zone electrophoresis,29,30 HPTLC,31–33 HPLC34–37 
and UV spectrophotometry29,38 have been reported for 
the estimation of QTF in pharmaceutical preparations. 
In the UV spectrophotometric method29 reported by 
Pucci et al., QTF was assayed in methanol after con-
verting the drug into its free base using a buffer of pH 
2.5 and the absorbance was measured at 246 nm. This 
method is applicable to determine the QTF in the  
concentration range 5–25 µg mL–1. Another UV method 
reported by Fursule et al.38 involves measurement of 
absorbance of QTF solution in water at 290 nm and in 
this method Beer’s law is obeyed in the range,  
6–54 µg mL–1. Since the buffer was used to convert 
QTF into its free base,29 due to incomplete conversion 
and extraction of base; and at shorter analytical wave-
length used, erratic results may obtained29,38 in addition 
to the method being less sensitive.38 Arulappa et al.39 
have reported a visible spectrophotometric method 
based on ion-pair complexation reaction with 
bromocresol green as reagent.  The ion-pair formed in 
acid medium was extracted into chloroform and meas-
ured at 415 nm over a concentration range of 5–25 µg 
mL–1 QTF. The method was applied to the determina-
tion of QTF in pharmaceuticals with narrow linear dy-
namic range and it was not applied to urine. Present 
authors have also reported two extraction-free spectro-
photometric methods40 for the determination of QTF in 
pure form and in its dosage forms. The procedures are 
applicable over the ranges of 1–20 (method A) and  
1.5–30 µg mL–1 (method B) QTF with molar absorptiv-
ity values of 2.97 × 104 and 1.97 × 104 L mol–1 cm–1. 
Though these methods are more sensitive, are applicable 
only for pure drug and tablets but not applied for spiked 
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human urine sample. Besides, the absorbance measure-
ments were made at 410 and 380 nm, which are some 
what shorter where the interferences from the excipients 
will be more.  
In the present investigation, the authors report the 
development and validation41 of an accurate, reproduci-
ble and sensitive extractive spectrophotometric method 
based on the formation of chloroform soluble ion-pair 
complex between QTF and quinoline yellow (QY; 
IUPAC Name: disodium 2-(1,3-dioxoinden-2-
yl)quinoline-6,8-disulfonate) (Figure 2) at pH 2.56. The 
method was applied to the determination of QTF in pure 
drug, tablets and spiked human urine. No interference 
was observed in the assay of QTF from common excipi-





A Systronics model 106 digital spectrophotometer  
(Systronics India Ltd, Ahmedabad, India) with 1 cm 
path length quartz cells and an Elico model L1-120 pH 
meter were used for the measurement of absorbance and 
pH values, respectively.  
 
Reagents and Solutions 
All chemicals used were of analytical reagent grade and 
solutions were prepared in distilled water. Chloroform 
(spectroscopic grade) was purchased form Merck, 
Mumbai, India. 
 
Quetiapine Fumarate (QTF) and its Tablets 
Pharmaceutical grade of QTF was kindly gifted by  
Cipla Ltd, Bangalore, India, and is certified to be  
99.5 % pure. It was used without further purification. 
Qutipin-200 and Qutipin-100 (both from Sun Pharma-
ceuticals Ltd, India) tablets were purchased from local 
market. 
 
Sulphuric Acid (H2SO4; 0.1 mol L
–1) 
Concentrated acid (S.D. Fine Chem, Mumbai, India, Sp. 
gr. 1.84) was appropriately diluted with water to get  
0.1 mol L–1. 
Hydrochloric Acid (HCl; 1 mol L–1) 
Concentrated acid (S.d. Fine Chem, Mumbai, India,  
Sp. gr. 1.18) was diluted appropriately with water to get  
1 mol L–1. 
 
Sodium Acetate (NaOAc; 1 mol L–1) 
A 1 mol L–1 solution was prepared by dissolving an 
accurately weighed amount of 13.6 g of pure sodium 
acetate trihydrate (S.D. Fine Chem Ltd, Mumbai, India) 
in 100 mL of water in a volumetric flask. 
 
Acetate-hydrochloride Buffer (pH 2.56) 
Fifty mL each of 1 mol L–1 NaOAc and 1 mol L–1 HCl 
were transferred into a 250 mL volumetric flask and the 
volume was made upto the mark with water. The pH of 
this solution was adjusted using HCl/NaOAc. 
 
Quinoline Yellow (QY) solution (500 µg mL–1) 
A 500 µg mL–1 solution of dye was prepared just before 
use by dissolving an accurately weighed quantity of QY 
(Loba Chemie Ltd, Mumbai, India, certified to be 70 % 
pure) in water and it was filtered. 
 
Urine Sample 
Drug-free human urine was obtained from a healthy 
male aged about 28 years. 
 
QTF Solution (100 and 50 µg mL–1) 
A stock standard solution of QTF was prepared by dis-
solving an accurately weighed 10 mg of pure drug in  
0.1 mol L–1 H2SO4 and the volume was made up to  
100 mL in a volumetric flask with the same acid to get 
100 µg mL–1 QTF. This solution was diluted appropri-
ately with 0.1 mol L–1 H2SO4 to get 50 µg mL
–1 QTF 
and used for the assay. 
 
General Recommended Procedures 
Into a series of 125 mL separating funnels, 0.5–5.0 mL 
aliquots of 50 µg mL–1 QTF standard solution were 
transferred by means of a microburette. The total vol-
ume in each separating funnel was adjusted to 5 mL by 
adding 0.1 mol L–1 H2SO4. To each funnel were added 
10 mL of water, 1 mL of 1 mol L–1 NaOAc, 4 mL buffer 
of pH 2.56 and 5 mL of dye solution. The content was 
mixed thoroughly, and after 5 min, the ion-pair complex 
was extracted with 10 mL of chloroform by shaking for 
30 seconds and the layers were allowed to separate. The 
















Figure 1. Chemical structure of QTF. 
 
 
Figure 2. Structure of quinoline yellow (QY). 
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sulphate and absorbance was measured at 420 nm 
against the reagent blank similarly prepared in the  
absence of QTF. The procedure was repeated three 
times and standard graph was prepared by plotting the 
absorbance versus drug concentration. The concentra-
tion of the unknown was read from the calibration graph 
or computed from the regression equation derived using 
the absorbance-concentration data. 
 
Procedure for Tablets 
Twenty tablets were weighed and pulverized. An 
amount of the tablet powder equivalent to 5 mg of QTF 
was weighed and transferred into a clean 100 mL  
volumetric flask containing ~70 mL 0.1 mol L–1 H2SO4. 
After shaking the content for 20 min, the volume was 
brought upto the mark with the same acid and filtered 
through Whatman No 42 filter paper. A suitable aliquot 
(say 3 mL) of this solution (50 µg mL–1 QTF) was  
subjected to analysis by using the general procedure 
described earlier. 
 
Procedure for Spiked Human Urine 
A 12.5 mL aliquot of 100 µg mL–1 QTF solution was 
mixed with 3 mL of urine and 2 mL of acetonitrile in a 
25 mL volumetric flask and the volume was made upto 
the mark with 0.1 mol L–1 H2SO4. The resulting solution 
was filtered through Whatman No 42 filter paper and 
three different aliquots of the filtered solution were 
subjected to analysis by following the general proce-
dure. The concentration of QTF in urine was found 
using standard graph or from the regression equation. 
 
Procedure for the Analysis of Placebo Blank and  
Synthetic Mixture 
A placebo blank containing starch (10 mg), acacia  
(15 mg), hydroxyl cellulose (10 mg), sodium citrate  
(10 mg), talc (20 mg), magnesium stearate (15 mg) and 
sodium alginate (10 mg) was made and its solution was 
prepared as described under tablets and then subjected 
to analysis. The absorbance of the placebo solution was 
almost equal to the absorbance of the blank which re-
vealed no interference from the excipients added to pure 
drug. 
A synthetic mixture was prepared by adding pure 
QTF (100 mg) to the above mentioned placebo blank 
and the mixture was homogenised. Synthetic mixture 
containing 5 mg of QTF was weighed and its solution in 
a 100 mL volumetric flask was prepared as described 
for tablets. Three different aliquots were subjected to 
analysis by following the general procedure. The con-
centration of QTF was found from the calibration graph 
or from the regression equation. 
 
RESULTS AND DISCUSSION 
The nitrogenous drugs are present in a positively 
charged protonated forms and anionic dyes are present 
mainly in anionic form at acidic pH. So, in acidic  
medium (pH 2.56) the protonated QTF (QTF. 2H++), 
forms an ion-pair complex with the anionic dye QY 
(QY– –) which is soluble in chloroform and showed 
maximum absorbance at 420 nm (Figure 3). Therefore, 
this wavelength was fixed as analytical λ and all absorb-
ance measurements were made at this wavelength. The 
possible reaction pathway for the formation of QTF-QY 
ion-pair complex is shown in Scheme 1.  
 
Optimisation of Reaction Conditions for Complex 
Formation 
Preliminary investigations were carried out to establish 
the most favourable conditions to give a highly intense 
colour which could be used for the quantitative determi-
nation of the drug. Optimum conditions were fixed by 
varying one parameter at a time while keeping other 
parameters constant and observing its effect on the ab-
sorbance at 420 nm against respective blank. The influ-
ence of each of the following variables on the reaction 
was tested. 
 
Effect of pH of Aqueous Phase and Volume of Buffer 
Solution 
The effect of pH of the aqueous phase on the absorb-
ance of QTF-QY ion-pair complex was studied by add-
ing different volumes of 1 mol L–1 NaOAc (0–5 mL) to 
the aqueous phase before adding dye solution and the 
effective pH of the aqueous phase was recorded. It was 
noticed that the maximum colour intensity and highest 
absorbance value for QTF-QY ion-pair complex were 
observed in the presence of 1 mL of 1 mol L–1 NaOAc. 
The effective pH of the aqueous phase in the presence 
of 1 mL of 1 mol L–1 NaOAc was measured to be  
2.56 ± 0.02. At lower and higher pH, the absorbance of 
the QTF-QY ion-pair complex started decreasing  
Figure 3. Absorption spectra of QTF-QY ion-pair complex
(15 µg mL−1 QTF) and blank. 
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(Figure 4a). Hence, pH 2.56 was fixed as optimum for 
complete formation of QTF-QY ion-pair complex. Var-
ious amounts of acetate-HCl buffer solution of pH 2.56 
were used in the investigation to establish its effect on 
absorbance. There was almost no influence on the ab-
sorbance from 3 to 6 mL of buffer but an amount less 
than 3 mL resulted in unsatisfactory separation of the 
organic phase during the extraction and lower absorb-
ance values (Figure 4b). So, 4 mL of buffer was used in 
the investigation. 
 
Effect of Reagent Concentration 
The influence of dye concentration on the absorbance of 
ion-pair complex was investigated by adding different 
volumes of 500 µg mL–1 QY solution (2–8 mL) to  
3 mL QTF (50 µg mL–1) solution. With volumes less 
than 4 mL, lower absorbance values were obtained and 
when the volume was greater than 6 mL, blank showed 
higher absorbance values and there was no clear separa-
tion of the two phases. A constant and maximum ab-
sorbance was obtained in the range of 4–6 mL of QY 
(Figure 5). Therefore, a 5 ml of 500 µg mL–1 QY solu-
tion in a total volume of 25 mL of aqueous phase was 
chosen as optimal for complete complexation. 
 
Effect of Extraction Solvent 
The effect of several organic solvents viz., chloroform, 
dichloromethane, carbon tetrachloride, 1,2-dichloro- 
ethane, hexane, ether, ethyl acetate and benzene was 
studied for the effective extraction of colored species 
from aqueous phase. Chloroform was found to be the 
most suitable for the extraction of colored complex, 
yielding maximum absorbance and considerably lower 
extraction ability for the reagent blank. 
Scheme 1. Probable reaction pathway for the formation of 1:1 ion-pair complex between QTF and QY. 
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Effect of Ratio of Aqueous to Organic Phases 
The effect of ratio of aqueous to organic phases was 
examined by adding 5–25 mL of water to 5 mL of QTF 
solution before the addition of dye solution. The extrac-
tion was performed in the presence of different volumes 
of chloroform (5–20 mL). Maximum and constant ab-
sorbance values were obtained with quick separation of 
two phases in the presence of 10–20 mL of water and  
10 mL of chloroform. Therefore, aqueous to organic 
phase ratio of 2.5:1 was used in the investigation. 
 
Number of Extractions 
It was observed that only one extraction with 10 mL 
portion of chloroform was adequate to achieve a quanti-
tative recovery of the complex and the shortest time to 
reach equilibrium between two phases. 
Reaction Time 
After the addition of dye, the effect of standing time on 
the complex formation was studied from 5 to 30 min 
before extraction. A contact time of 5 min was found 
adequate for full complex formation. 
 
Effect of Shaking Time 
The effect of shaking time on the extraction of QTF-QY 
ion-pair was studied by shaking separating funnel for 
different times ranging from 30 to 180 s after adding 
chloroform. Constant absorbance readings were  
obtained from 45 s and onwards and, hence a 60 s  
shaking time was fixed. 
 
Equilibration Time and Stability of the Coloured 
Complexes 
The organic and aqueous phases were clearly separated 
in less than 1 min. The drug-dye ion-pair complex was 
stable for more than 2 h at laboratory temperature 
(30 ± 2 ºC).  
 
Effect of Order of Addition of Reactants 
The sequence of order of addition of reactants prior to 
extraction had very little effect on the absorbance. So 
the order of addition of reactants should be in the  
described manner. 
 
Composition of Ion-pair Complex 
The composition of the ion-pair complex was  
established by Job’s method of continuous variations42 
using equimolar concentrations of drug and dye  
(5.52 × 10–4 mol L–1). The results indicated that 1:1 
(drug:dye) ion-pair is formed through the electrostatic 
attraction between the positive protonated drug and 
Figure 4. Effect of: a) pH and b) volume of buffer on the absorbance of QTF-QY ion-pair complex. 
Figure 5. Effect of volume of dye on the absorbance of ion-
pair complex (15 µg mL–1). 
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anionic dye. Seven solutions containing QTF and QY in 
various molar ratios, with a total volume of 5 mL, in 
addition to 10 mL of H2O, 1 mL of 1 mol L
–1 NaOAc 
and 4 mL of buffer solution, were prepared. The extrac-
tion was performed using 10 mL of chloroform and the 
absorbance was subsequently measured at 420 nm. The 
graph of the results obtained (Figure 6) gave a maxi-
mum at a molar ratio of Xmax = 0.5 which indicated the 
formation of 1:1 QTF:QY ion-pair complex. 
 
Conditional Stability Constant (Kf) of the Ion-pair 
Complex 
The conditional stability constant (Kf) of the ion-pair 
formed by QTF with QY was calculated from the  








where A is the maximum observed absorbance and Am is 
the absorbance value when whole amount of drug is 
associated. CM is the mole concentration of drug at the 
maximum absorbance and n is the combination ratio of 
ion-pair considered. The log Kf value obtained for the 
QTF-QY ion-pair, on three determinations is  
5.12 ± 0.56. 
 
METHOD VALIDATION 
Linearity, Sensitivity, Limits of Detection and  
Quantification 
Calibration graph was constructed from six points cov-
ering the concentration range 2.5–25.0 µg mL–1.  
Regression analysis of the Beer’s law data indicated a 
linear relationship between absorbance and concentra-
tion, (Table 1) which is corroborated by high value 
(close to unity) of the correlation coefficient. A plot of 
log absorbance and log concentration yielded a straight 
line with slope equal to 1.1, further establishing the 
linear relation between the two variables. The calculated 
molar absorptivity and Sandell sensitivity44 values are 
summarized in Table 1. The limits of detection (LOD) 
and quantification (LOQ) were calculated using the 
formulae: LOD = 3.3 S/b and LOQ = 10 S/b, (where S is 
the standard deviation of blank absorbance values, and b 
is the slope of the calibration plot), calculated according 
to the ICH guidelines41 are also summarized in Table 1. 
The high value of ε and low value of Sandell sensitivity 
and LOD indicates the high sensitivity of the proposed 
method. 
 
Precision and Accuracy 
The assay described under “General Procedure” was 
repeated seven times within the day to determine the 
repeatability (intra-day precision) and five times on 
different days to determine the intermediate precision 
(inter-day precision) of the method. The assay was per-
formed on three levels of analyte. The results of this 
study are summarized in Table 2. The percentage rela-
tive standard deviation (RSD / %) values were ≤ 2.55 % 
(intra-day) and ≤ 2.88 % (inter-day) indicating high 
 
Figure 6. Job’s method of continuous variation graph for the
ion-pair complexation reaction of QTF with QY.
[QTF] = [QY] = 5.52 × 10−4 mol L–1. 
Table 1. Sensitivity and regression parameters 
Parameter Value
max / nm 420 
Linear range / µg mL–1 2.5–25.0 
Molar absorptivity (ε) / L mol–1 cm–1 2.02 × 104 
Sandell sensitivity* / µg cm–2 0.0304 
Limit of detection (LOD) / g mL–1 0.11 
Limit of quantification (LOQ) / g mL–1 0.33 
Regression equation, Y**  
Intercept (a) –0.013 
Slope (b) 0.0346 
Standard deviation of a (Sa) 0.0284 
Standard deviation of b (Sb) 0.0020  
Variance (Sa
2) 8.1 × 10–4 
Regression coefficient (r) 0.9990 
*Limit of determination as the weight in µg per mL of solu-
tion, which corresponds to an absorbance of A = 0.001 meas-
ured in a cuvette of cross-sectional area 1 cm2 and l = 1 cm.  
**A = bx + a, Where A is the absorbance, x is concentration in 
µg mL–1, a is intercept and b is slope. 
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precision of the method. The accuracy of the method 
was determined by the percent mean deviation from 
known concentration, bias % = [(concentration found – 
known concentration) × 100 / known concentration]. 
Bias was calculated at each concentration and these 
results are also presented in Table 2. Percent relative 
error (RE / %) values ≤ 3.60 % demonstrate the high  
accuracy of the proposed method. 
 
Selectivity 
The results obtained from placebo blank and synthetic 
mixture analyses revealed that the inactive ingredients 
used in the preparation did not interfere in the assay of 
active ingredient. The absorbance values obtained from 
the placebo blank solution were almost equal to the 
absorbance of the blank which revealed no interference 
from the adjuvants. To study the role of additives added 
to the synthetic sample, 3 mL of the resulting solution 
prepared by using synthetic mixture containing  
50 µg mL–1 of QTF was assayed (n = 4). The yielded 
recoveries of 94.00–102.7 % with RSD values in the 
range 0.99–2.83 % demonstrated the accuracy as well as 
the precision of the proposed method and complement 
the findings of the placebo blank analysis with respect 
to selectivity. 
Robustness and Ruggedness 
The robustness of the method was evaluated by making 
small incremental changes in volume of dye, buffer and 
contact time, and the effect of these changes on the 
absorbance of the colored systems was studied. The 
changes had negligible influence on the results as re-
vealed by small intermediate precision values expressed 
as RSD (≤ 2.55 %). Method ruggedness was demon-
strated by having the analysis done by four analysts, and 
also by a single analyst performing analysis on four 
different instruments in the same laboratory. Intermedi-
ate precision values (RSD) of this study were in the 
range 1.89–3.21 % indicating acceptable ruggedness. 
The results are presented in Table 3. 
 
Application to Tablets 
The proposed method was applied for the quantification 
of QTF in commercial tablets. The results obtained were 
compared with those obtained using a conventional UV 
spectrophotometric method,29 where the absorbance of 
the methanolic solution of QTF was measured at  
246 nm. Statistical analysis of the results did not detect 
any significant difference in the performance of the 
proposed method to the reference method with respect 
Table 2. Evaluation of intra-day and inter-day accuracy and precision 
QTF taken /  
µg mL–1 
Intra-day accuracy and precision  






Inter-day accuracy and precision 





found ± CL /   
µg mL–1
 RE / %  RSD / %  
QTF 
found ± CL /  
µg mL–1
  RE / %   RSD / % 
10.0  10.27±0.19  2.67  1.97  10.36±0.27  3.60  2.08 
15.0 
 
 15.51±0.37  3.40 2.55 15.48±0.55  3.20 
 
 2.88 
20.0   19.69±0.20  1.53 1.10 20.15±0.49  0.75 
 
 1.98 
RE / % − percent relative error; RSD / % − relative standard deviation and CL − confidence limits were calculated from: 
CL = ± tS/√n. (The tabulated value of t is 2.45 and 2.77 for six and four degrees of freedom respectively, at the 95 % confidence 
level; S = standard deviation and n = number of measurements). 
 
Table 3. Method robustness and ruggedness expressed as intermediate precision (RSD / %) 
QTF taken / µg mL–1  
 Robustness   Ruggedness 




(RSD / %),  





(RSD / %), 
(n = 4) 
Volume of 
Dye* 
     Volume of   
     buffer** 
   Reaction  
   time# 
10.0  2.34  2.55  2.26  2.45  3.21 
15.0  1.40  1.86  1.95  3.10  1.89 
20.0  0.85  2.10  1.55  2.85  2.11 
*The volumes of dye used were 5 ± 1.0 ml.  
**The volumes of buffer used were 4 ± 0.5 mL.  
#The reaction times were 5 ± 1.0 min. 
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to accuracy and precision as revealed by the Student’s  
t-value and variance ratio F-value.45 The results of this 
study are given in Table 4. 
 
Application to Spiked Human Urine 
The proposed method was applied to the determination 
of QTF in spiked human urine by following the general 
procedure described above. The recovery of the drug 
from spiked urine analysis was calculated by triplicate 
analysis of urine sample containing 10, 15 and  
20 µg mL–1 QTF separately. The percentage recovery 
values of 98.40–103.1 with standard deviation  
0.84–1.48 % showed the non-interference of other mate-
rials present in urine to the assay of QTF with consider-
able accuracy. The analytical results obtained for QTF 
in human urine sample are presented in Table 5. 
 
Recovery Study 
To further assess the accuracy of the proposed method, 
recovery experiment was performed by applying the 
standard-addition technique. The recovery was assessed 
by determining the agreement between the measured 
standard concentration and added known concentration 
to the sample. The test was done by spiking the pre-
analysed tablet powder with pure QTF at three different 
levels (50, 100 and 150 % of the content present in the 
tablet powder (taken) and the total was found by the 
proposed method. Each test was repeated three times. 
From this test the percentage recovery values were 
found in the range of 95.95–104.2 with standard devia-
tion values from 0.26 to 1.2 %. Closeness of the results 
to 100 % showed the fairly good accuracy of the meth-
od. These results are shown in Table 6. 
 
CONCLUSIONS 
The dye, quinoline yellow has been utilized as ion-pair 
reagent for the determination of quetiapine fumarate in 
pure drug, tablets and spiked human urine sample. The 
proposed method is simple and the maximum color 
development of QTF-QY ion-pair complex is instanta-
neous. No heating or long standing time was needed. 
The method does not involve procedural steps, do not 
take more operator time and expertise like HPLC and 
other methods. In terms of simplicity, rapidity, sensitivi-
ty and cost, the method can be considered superior to 
the previously reported methods, especially with those 
based on chromatography.31–37 The reagent utilized in 
the proposed method is cheaper, readily available and 
the procedure does not involve any critical reaction 
conditions or tedious sample preparation. The method is 
unaffected by slight variations in experimental condi-
tions such as time and reagent concentration. The pro-
posed method gave results with good accuracy to permit 
determination of low concentration even down to  
0.11 µg mL–1 QTF. Since there was no interference 
from the tablet excipients and numerous substances 
present in urine, the method is highly selective for the 
determination of QTF in quality control laboratories and 
physiotherapeutic analysis. 
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Table 4. Results of analysis of tablets by the proposed method 

















200   200  97.16±1.28  
98.36±0.86
t = 1.77 
F = 2.22
Qutipin-
100   100  100.6±1.27  
101.3±0.54
t = 1.22 
F = 5.53
*Mean value of 5 determinations. 
(Tabulated t-value at the 95 % confidence level and for four 
degrees of freedom is 2.77). (Tabulated F-value at the 95 % 
confidence level and for four degrees of freedom is 6.39). 
ψMarketed by: Sun Pharmaceuticals Ltd, India. 
 



















9.72 5.0 14.93 104.2±1.20 
9.72 10.0 19.32 95.95±0.26 
9.72 15.0 24.86 100.9±0.87 
*Mean value of three determinations. 
 
Table 5. Application of the proposed method to QTF concen-
tration measurements in spiked human urine 
QTF added / 
µg mL–1 
QTF found* / 
µg mL–1 
Recovery




*Mean value of three determinations. 
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